Advaxis, Inc. Form 8-K July 29, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

July 29, 2008 (Date of Earliest Event Reported)

Advaxis, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 00028489 (Commission File Number) 02-0563870 (IRS Employer Identification No.)

Technology Centre of New Jersey 675 Rt. 1, Suite B113 North Brunswick, N.J. 08902 (Address of principal executive offices)

(732) 545-1590 (Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

0	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events

On July 29, 2008, Advaxis, Inc issued a press release regarding its Investigational New Drug application for Lovaxin C.

A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by this reference.

Item 9.01Financial Statements and Exhibits

99.1

Advaxis, Inc. press release, dated July 29, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 29, 2008

Advaxis, Inc.

By: /s/ Thomas A. Moore

Name: Thomas A. Moore Title: Chief Executive Officer